Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis

• Published in: Clinical colorectal cancer 2021-09, Vol.20 (3), p.236-244
• Main Authors: Hanna, Catherine R., Robles-Zurita, Jose A., Briggs, Andrew, Harkin, Andrea, Kelly, Caroline, McQueen, John, Allan, Karen, Pearson, Sarah, Hollander, Henrik, Glimelius, Bengt, Salazar, Ramon, Segelov, Eva, Saunders, Mark, Iveson, Tim, Jones, Robert J., Boyd, Kathleen A.
• Format: Article
• Language: English
• Subjects: Chemotherapy, Adjuvant; Clinical trial; Colorectal Neoplasms - drug therapy; Cost analysis; Cost-Benefit Analysis; Drug therapy; Humans; International; Neoplasm; Oxaliplatin - therapeutic use; Quality of Life; Quality-Adjusted Life Years
• ISSN: 1533-0028; 1938-0674
• DOI: 10.1016/j.clcc.2021.04.001

The Short Course Oncology Treatment (SCOT) trial demonstrated non-inferiority, less toxicity, and cost-effectiveness from a UK perspective of 3 versus 6 months of oxaliplatin-based chemotherapy for patients with colorectal cancer. This study assessed the cost-effectiveness of shorter treatment and the budget impact of implementing trial findings from the perspectives of all countries recruited to SCOT: Australia, Denmark, New Zealand, Spain, Sweden, and the United Kingdom. Individual cost–utility analyses were performed from the perspective of each country. Resource, quality of life, and survival estimates from the SCOT trial (N = 6065) were used. Probabilistic sensitivity analysis and subgroup analyses were undertaken. Using undiscounted costs from these cost–utility analyses, the impact on country-specific healthcare budgets of implementing the SCOT trial findings was calculated over a 5-year period. The currency used was US dollars (US$), and 2019 was the base year. One-way and scenario sensitivity analysis addressed uncertainty within the budget impact analysis. Three months of treatment were cost saving and cost-effective compared to 6 months from the perspective of all countries. The incremental net monetary benefit per patient ranged from US$8972 (Spain) to US$13,884 (Denmark). The healthcare budget impact over 5 years for the base-case scenario ranged from US$3.6 million (New Zealand) to US$61.4 million (UK) and totaled over US$150 million across all countries. This study has widened the transferability of results from the SCOT trial, showing that shorter treatment is cost-effective from a multi-country perspective. The vast savings from implementation could fully justify the investment in conducting the SCOT trial. This study widens the transferability of cost–utility results from the SCOT trial showing that administering 3 months of adjuvant, oxaliplatin-based chemotherapy is cost-effective and cost saving compared to 6 months from the perspective of all countries recruited to SCOT. The impact on healthcare budgets if the findings are implemented as predicted will amount to savings of at least US$150 million over 5 years.